Loading patent…
AssigneeMemorial Sloan Kettering Cancer Center
InventorPrasad S. Adusumilli
Estimating the term…
Disclosed herein are cells that are immune cells, which cells recombinantly express a dominant negative form of an inhibitor of a cell-mediated immune response of the immune cell, and optionally recombinantly express a chimeric antigen receptor (CAR), wherein the CAR binds to a viral antigen. In certain embodiments, the immune cell is an immunostimulatory cell, such as a T cell. In certain embodiments, the immune cell is an immunoinhibitory cell, such as a regulatory T cell. Also disclosed herein are immune cells that recognize and are sensitized to a viral antigen, which immune cells recombinantly express a dominant negative form of an inhibitor of a cell-mediated immune response of the immune cell. The cells can be sensitized to an antigen that is a viral antigen. Additionally provided are methods of using such cells to treat a viral infection in a subject in need thereof.
A cell that is an immunostimulatory cell or precursor cell thereof, which cell recombinantly expresses (a) a chimeric antigen receptor (CAR), and (b) a dominant negative form of an inhibitor of a cell-mediated immune response of the immunostimulatory cell, wherein the CAR binds to a viral antigen.
A population of immunostimulatory cells or precursor cells thereof, which cell population comprises cells that recombinantly express (a) a chimeric antigen receptor (CAR), and (b) a dominant negative form of an inhibitor of a cell-mediated immune response of the immunostimulatory cell, wherein the CAR binds to a viral antigen.
A T cell that recognizes and is sensitized to a viral antigen, which T cell recombinantly expresses a dominant negative form of an inhibitor of a T cell-mediated immune response.
A population of T cells, which cell population comprises T cells that recognize and are sensitized to a viral antigen and which recombinantly express a dominant negative form of an inhibitor of a T cell-mediated immune response.
A regulatory T cell that recognizes and is sensitized to a viral antigen, which regulatory T cell recombinantly expresses a dominant negative form of an inhibitor of a regulatory T cell-mediated immune response.
A population of regulatory T cells, which cell population comprises T cells that recognize and are sensitized to a viral antigen and which recombinantly express a dominant negative form of an inhibitor of a regulatory T cell-mediated immune response.
A regulatory T cell isolated from a subject having a viral infection, which regulatory T cell recombinantly expresses a dominant negative form of an inhibitor of a regulatory T cell-mediated immune response.
A population of regulatory T cells isolated from a subject having a viral infection, which cell population comprises regulatory T cells which recombinantly express a dominant negative form of an inhibitor of a regulatory T cell-mediated immune response.
An immunoinhibitory cell, which cell is isolated from a subject having a viral infection, which immunoinhibitory cell recombinantly expresses a dominant negative form of an inhibitor of an immunoinhibitory cell-mediated immune response.
A population of immunoinhibitory cells isolated from a subject having a viral infection, which cell population comprises immunoinhibitory cells which recombinantly express a dominant negative form of an inhibitor of an immunoinhibitory cell-mediated immune response.
A polyclonal population of human regulatory T cells that are CD4+CD25+, are sensitized to a viral antigen, and recombinantly express a dominant negative form of an inhibitor of a regulatory T cell-mediated immune response.
A cell that is an immunostimulatory cell or precursor cell thereof, which cell recombinantly expresses:
A population of immunostimulatory cells or precursor cells thereof, which cell population comprises cells that recombinantly express:
An immunoinhibitory cell, which cell is isolated from a subject having a viral infection, which immunoinhibitory cell recombinantly expresses:
A population of immunoinhibitory cells isolated from a subject having a viral infection, which cell population comprises immunoinhibitory cells which recombinantly express:
A cell that is an immunostimulatory cell or precursor cell thereof, which cell recombinantly expresses (a) a chimeric antigen receptor (CAR), and (b) a dominant negative form of an inhibitor of a cell-mediated immune response of the immunostimulatory cell, wherein the CAR binds to an antigen of a pathogen.
A population of immunostimulatory cells or precursor cells thereof, which cell population comprises cells that recombinantly express (a) a chimeric antigen receptor (CAR), and (b) a dominant negative form of an inhibitor of a cell-mediated immune response of the immunostimulatory cell, wherein the CAR binds to an antigen of a pathogen.
A T cell that recognizes and is sensitized to an antigen of a pathogen, which T cell recombinantly expresses a dominant negative form of an inhibitor of a T cell-mediated immune response.
A population of T cells, which cell population comprises T cells that recognize and are sensitized to an antigen of a pathogen and which recombinantly express a dominant negative form of an inhibitor of a T cell-mediated immune response.
A method of treating a viral infection in a subject in need thereof, comprising:
A method of treating a viral infection in a subject in need thereof, comprising:
A method of treating a viral infection in a subject in need thereof, comprising:
A method of treating a viral infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of:
A method of treating a viral infection in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of:
Dependencies are inferred from the claim text.